Zymeworks (ZYME) Net Cash Flow (2021 - 2026)
Zymeworks recorded quarterly Net Cash Flow of $203.0 million in Q1 2026, up 959.08% quarter-over-quarter from -$23.6 million in Q4 2025, and up 1911.96% year-over-year from $10.1 million in Q1 2025.
Zymeworks' Net Cash Flow history runs 6 years deep, the most recent figure standing at $203.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 1911.96% year-over-year to $203.0 million; the TTM figure through Mar 2026 stood at $168.0 million (up 533.23% YoY), while the FY2025 annual figure was -$24.9 million, up 72.86% from the prior year.
- Net Cash Flow came in at $203.0 million for Q1 2026 at Zymeworks, up from -$23.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $304.9 million in Q4 2022 to a low of -$219.7 million in Q1 2023.
- A 5-year average of $2.4 million and a median of -$33.5 million in 2025 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow slumped 397.78% in 2023 and surged 1911.96% in 2026, its largest moves.
- Zymeworks' Net Cash Flow stood at $304.9 million in 2022, then slumped by 79.26% to $63.2 million in 2023, then tumbled by 189.15% to -$56.4 million in 2024, then soared by 58.07% to -$23.6 million in 2025, then surged by 959.08% to $203.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $203.0 million, -$23.6 million, and -$33.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 203.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 203.03 Mn |
| Mar 31, 2026 | 203.03 Mn |
| Dec 31, 2025 | -23.63 Mn |
| Dec 31, 2025 | -23.63 Mn |
| Sep 30, 2025 | -33.50 Mn |
| Sep 30, 2025 | -33.50 Mn |
| Jun 30, 2025 | 22.14 Mn |
| Jun 30, 2025 | 22.14 Mn |
| Mar 31, 2025 | 10.09 Mn |
| Mar 31, 2025 | 10.09 Mn |
| Dec 31, 2024 | -56.37 Mn |
| Dec 31, 2024 | -56.37 Mn |
| Sep 30, 2024 | 51.40 Mn |
| Sep 30, 2024 | 51.40 Mn |
| Jun 30, 2024 | -43.91 Mn |
| Jun 30, 2024 | -43.91 Mn |
| Mar 31, 2024 | -42.86 Mn |
| Mar 31, 2024 | -42.86 Mn |
| Dec 31, 2023 | 63.23 Mn |
| Dec 31, 2023 | 63.23 Mn |
| Sep 30, 2023 | -47.79 Mn |
| Sep 30, 2023 | -47.79 Mn |
| Jun 30, 2023 | -39.47 Mn |
| Jun 30, 2023 | -39.47 Mn |
| Mar 31, 2023 | -219.68 Mn |
| Mar 31, 2023 | -219.68 Mn |
| Dec 31, 2022 | 304.92 Mn |
| Dec 31, 2022 | 304.92 Mn |
| Sep 30, 2022 | -102.82 Mn |
| Sep 30, 2022 | -102.82 Mn |
| Jun 30, 2022 | -77.03 Mn |
| Jun 30, 2022 | -77.03 Mn |
| Mar 31, 2022 | 73.77 Mn |
| Mar 31, 2022 | 73.77 Mn |
| Dec 31, 2021 | -51.68 Mn |
| Dec 31, 2021 | -51.68 Mn |